Chi-Chiu Mok is the chief of the Division of Rheumatology, Department of Medicine, Tuen Mun Hospital, Hong Kong. He is a consultant physician and adjunct professor of the University of Hong Kong and the Chinese University of Hong Kong. An active researcher, Dr. Mok is the first author of more than 200 papers in various Rheumatology journals that include Lancet Rheumatology, Annals of the Rheumatic Diseases, Nature Review Rheumatology, Arthritis and Rheumatology and Rheumatology (Oxford). His research interests are systemic lupus erythematosus, particularly lupus nephritis, and glucocorticoid induced osteoporosis. Dr. Mok is also the principal investigator of a number of phase II/III global trials investigating the safety and efficacy of novel biological agents in various rheumatic diseases. Dr. Mok is the senior associate editor of the International Journal of Rheumatic Diseases, Therapeutic Advances in Musculoskeletal Diseases and an editorial member of >10 medical journals that include the Journal of Rheumatology, Lupus and Current Rheumatology Review. Dr. Mok is a Past President of the Hong Kong Society of Rheumatology. He is the founder editor of the Journal of Clinical Rheumatology and Immunology, the official publication of the Hong Kong Society of Rheumatology.
Research & Clinical Focus
[Breakfast Symposium V - Astellas] Lupus Nephritis
Calcineurin inhibitors in systemic lupus erythematosus: A revisit